A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer
Kathryn E. Maraszek, Arwen A. Tisdale, Hunter D. Reavis, Xiaozhuo Liu, Eduardo Cortes Gomez, Alexander A. Dolskiy, Caneta Brown, Daksh Thakkar, Maura Dungan, Anusha Adhikari, Emily E. Mackey, Janusz Franco‐Barraza, Brooke Pereira, Paul Timpson, Dean G. Tang, , Michael E. Feigin
This study identifies an opioid-mediated signaling axis in pancreatic cancer that drives extracellular matrix remodeling and tumor aggressiveness, suggesting methylnaltrexone as a potential therapeutic.
bioRxiv · May 21, 2026 · PreprintCancer Biology